Kleban, Sarah External Entity

Publications

Sort by

Selected publications

  • Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.  Clinical cancer research : an official journal of the American Association for Cancer Research2001 Academic Article GET IT
    Times cited: 17

Other